NanoViricides, Inc. (NYSE American: NNVC) has spotlighted its drug candidate NV-387 as a potential game-changer in the fight against measles, a disease experiencing alarming outbreaks across the United States, Canada, the UK, and the European Union. With measles cases in the U.S. hitting 1,319 in 2025, surpassing the 2019 record, and Canada reporting over 3,800 cases, the urgency for an effective treatment has never been more critical. The World Health Organization (WHO) noted 127,350 cases in Europe in 2024, marking the highest incidence since 1997.
NV-387, developed using NanoViricides' host-mimetic nanomedicine technology, has demonstrated effectiveness and safety in animal studies and completed a Phase I clinical trial with no adverse events, indicating strong human tolerability. The company believes NV-387 may qualify for Orphan Drug and Fast Track designations, which could expedite its approval process and grant seven years of market exclusivity. This development is particularly significant as there is currently no approved drug for measles, and vaccination rates are being challenged by hesitancy and immune dysfunction.
The potential of NV-387 to address this critical medical need is underscored by the growing global measles crisis. For more information on NanoViricides' groundbreaking work, visit https://www.NanoViricides.com. The latest updates on NNVC can be found in the company’s newsroom at https://ibn.fm/NNVC.
